Tian Guoqing, Guo Leilei, Gao Weimin
Department of Traditional Chinese Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Curr Drug Discov Technol. 2010 Mar;7(1):32-6. doi: 10.2174/157016310791162776.
Traditional Chinese/herbal medicine (TCM) is now commonly used by cancer patients of Asian ethnicity to supplement or replace prescribed treatments. The overall survival rate for lung cancer has not improved significantly in the past several decades; it remains the leading cause of cancer death. Much more attention has been paid by clinicians and researchers to the possible use of compound Chinese medicine (CCM) as effective anti-lung cancer medicines. In this review, we briefly summarize the clinical and experimental status of numerous CCMs recently developed primarily in China for the treatment of lung cancer, including formulations, treatment effectiveness, and molecular mechanisms. By presenting this information, our goal is to possibly open up new future avenues for the practice of lung cancer treatment.
传统中医/草药医学(TCM)目前被亚裔癌症患者普遍用于补充或替代规定的治疗方法。在过去几十年中,肺癌的总体生存率并未显著提高;它仍然是癌症死亡的主要原因。临床医生和研究人员更加关注复方中药(CCM)作为有效的抗肺癌药物的可能用途。在本综述中,我们简要总结了最近主要在中国开发的用于治疗肺癌的众多复方中药的临床和实验状况,包括配方、治疗效果和分子机制。通过展示这些信息,我们的目标是可能为肺癌治疗实践开辟新的未来途径。